Related Experiment Videos
Ursodeoxycholic acid for chronic liver diseases.
M Podda1, C Ghezzi, P M Battezzati
1Instituto di Medicina Interna, University of Milan, Italy.
Journal of Clinical Gastroenterology
|January 1, 1988
Summary
Ursodeoxycholic acid (UDCA) effectively improves liver function in patients with chronic liver diseases. Lower doses of UDCA show significant benefits, with higher doses providing further improvement in liver enzyme levels.
Area of Science:
- Hepatology
- Biochemistry
Background:
- Bile acids exhibit varying hepatotoxicity based on hydroxylation and orientation.
- Ursodeoxycholic acid (UDCA) is used in chronic liver disease to increase bile acid pool hydrophilicity.
- Previous studies suggest UDCA efficacy at 10-15 mg/kg/day for primary biliary cirrhosis and chronic hepatitis.
Purpose of the Study:
- To determine the optimal dosage of UDCA for chronic hepatitis and anicteric primary biliary cirrhosis.
- To investigate the dose-response relationship of UDCA in improving liver function indices.
- To assess the effect of UDCA on bile acid pool composition.
Main Methods:
- A study involving 18 patients with primary biliary cirrhosis and 12 with chronic hepatitis.
- Patients received escalating daily doses of UDCA (250, 500, and 750 mg) over three consecutive 2-month periods.
- Serum enzyme levels and bile acid pool composition were analyzed.
Main Results:
- Significant decreases in serum enzyme levels were observed even at the lowest dose of 250 mg/day UDCA.
- Higher doses of UDCA led to further improvements in liver function indices.
- Observed improvements correlated with increased enrichment of conjugated bile acids with UDCA.
Conclusions:
- Lower doses of UDCA (250 mg/day) are effective in treating chronic hepatitis and primary biliary cirrhosis.
- UDCA treatment favorably alters bile acid pool composition, reducing hepatotoxic bile acids.
- Optimal dosing strategies for UDCA in chronic liver disease can be established through further studies.